Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib, Rituximab, and Intravitreal Methotrexate in PVRL
NCT04899453Phase 2Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Aug 2020
- Primary completion
- Aug 2022
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of zanubrutinib in primary vitreoretinal lymphoma (PVRL), sponsored by Peking Union Medical College Hospital. Status: unknown.
02
Drugs
zanubrutinib
03
Conditions
primary vitreoretinal lymphoma (PVRL)
Beyond the preview
Go deeper on NCT04899453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04899453.